DermTech Income Statement 2023-2011 | DMTK

Brief overview of profit and loss at DermTech

This overview is based on financial performance over the past five years. DermTech reported revenue of $2.4 million in 2018 and $15.3 million by 2023. The five-year change reached +526.4%, while CAGR stood at 44.3%. The annual growth rate indicates an exceptionally strong top-line trend.

The gross result shifted from −$185 thousand to $276 thousand, or +249.2%. The cost base moved more slowly than the top line, which supported margins. Gross profit as a share of revenue changed from −7.6% to 1.8%. A wider margin shows that the economics of the core business improved.

The operating result measured by EBITDA moved from −$8.5 million to −$104 million, or −1120.4%. Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from −347.4% to −676.9%. Operating return per unit of revenue declined.

The final result was −10 million dollars initially and −101 million dollars in the final year. The loss widened and increased the financial risk.

The five-year change in capitalization reached −53%: from $90.2 million to $42.4 million. Investors remain cautious despite better financial results.

Financial takeaway

The financial trajectory is weak and requires a cautious interpretation. The financial profile benefits from a larger revenue base and a stronger gross margin. The main areas of concern are a narrow gross-profit buffer, weaker operating efficiency and lower investor confidence. Investors should continue to monitor margins, costs, and earnings quality.